|
?:authorAffiliation
|
-
[\'Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.\', \'Department of Medicine, University of Cambridge, Cambridge, UK.\', \'Division of Infection and Immunity, University College London, London, UK.\', \'Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.\', \'Department of Biochemistry, University of Washington, Seattle, WA, USA.\', \'Vir Biotechnology, San Francisco, CA, USA.\', \'Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.\', \'Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy.\', \'NIHR Cambridge Clinical Research Facility, Cambridge, UK.\', \'NIHR Bioresource, Cambridge, UK.\', \'University of Kent, Canturbury, UK.\', \'Department of Clinical Biochemistry and Immunology, Addenbrooke\'s Hospital, Cambridge, UK.\', \'Laboratorio de Inmunologia, UNAM, Cuautitlán, Mexico.\', \'Institute of Biodiversity, University of Glasgow, Glasgow, UK.\', \'Department of Haematology, University of Cambridge, Cambridge, UK.\', \'Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.\', \'Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. rkg20@cam.ac.uk.\', \'Department of Medicine, University of Cambridge, Cambridge, UK. rkg20@cam.ac.uk.\', \'Department of Haematology, University of Cambridge, Cambridge, UK. rkg20@cam.ac.uk.\', \'University of KwaZulu Natal, Durban, South Africa. rkg20@cam.ac.uk.\', \'Africa Health Research Institute, Durban, South Africa. rkg20@cam.ac.uk.\', \'Department of Infectious Diseases, Cambridge University Hospitals NHS Trust, Cambridge, UK. rkg20@cam.ac.uk.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}